U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C12H24O11.H2O
Molecular Weight 362.3276
Optical Activity UNSPECIFIED
Defined Stereocenters 9 / 9
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LACTITOL MONOHYDRATE

SMILES

O.OC[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO

InChI

InChIKey=LXMBXZRLTPSWCR-XBLONOLSSA-N
InChI=1S/C12H24O11.H2O/c13-1-4(16)7(18)11(5(17)2-14)23-12-10(21)9(20)8(19)6(3-15)22-12;/h4-21H,1-3H2;1H2/t4-,5+,6+,7+,8-,9-,10+,11+,12-;/m0./s1

HIDE SMILES / InChI

Description

Lactitol is a sugar alcohol. This ingredient has been determined to be GRAS for specified uses as a direct food additive and foods containing lactitol are eligible for a health claim related to dental caries. Lactitol is used as an oral powder or solution in the management of hepatic encephalopathy and in case of short-term treatment of occasional constipation. Intestinal flora of large intestine is metabolize lactitol to low-molecular organic acid, which leads to an increase in osmotic pressure in intestine, increase in volume of fecal masses bowel function normalization. This drug might cause abdominal discomfort, especially flatulence and abdominal pain rarely or sometimes abdominal distension. These effects tend to diminish or disappear after a few days of regular intake of the drug. Since 'antacids and neomycin can neutralize ' acidifying effect of lactitol on stool, they should not be co-administered with lactitol in cirrhotic patients with hepatic encephalopathy; however both substances do not alter the 'laxative effect in patients with constipation.

Originator

Approval Year

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Importal
Primary
Importal

Cmax

ValueDoseCo-administeredAnalytePopulation
776 ng/mL
20 g single, oral
LACTITOL serum
Homo sapiens
2780 ng/mL
21 g single, oral
LACTITOL plasma
Homo sapiens
776 ng/mL
21 g single, oral
LACTITOL plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
6.019 ng × h/mL
20 g single, oral
LACTITOL serum
Homo sapiens
14941 ng × h/mL
21 g single, oral
LACTITOL plasma
Homo sapiens
6019 ng × h/mL
21 g single, oral
LACTITOL plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
2.4 h
20 g single, oral
LACTITOL serum
Homo sapiens
2.16 h
21 g single, oral
LACTITOL plasma
Homo sapiens
2.43 h
21 g single, oral
LACTITOL plasma
Homo sapiens

Doses

AEs

PubMed

Sample Use Guides

In Vivo Use Guide
Initial dose - 20 g at once during 4-5 days. Next, 10 g per day.
Route of Administration: Oral
In Vitro Use Guide
The species of bifidobacteria, which were detected in vessel of each fermentation after adaptation to an Lactitol 1% (wt/vol): Bifidobacterium adolescentis, B. bifidum, B. longum, B. dentium and B. catenulatum. B. angulatum, B. breve and B. infantis were not detected.